Join our Young CRC Patient Focus Group This year, DiCE is working on gaining additional insight into the experiences of young colorectal cancer patients, from symptoms to diagnosis to […]

Shaping Priorities for the EU4Health Funding Programme The Commission conducted in May a targeted consultation on the EU4Health programme’s future priorities, orientation, and needs. DiCE contributed […]

Croatian National Policy Event on Digestive Cancers

SURVEY: Assessing AI Awareness & Perceptions Among Patient Organisations European Patient’s Forum (EPF) is collecting responses to a survey addressed to patients’ organisations or individuals carrying out patient advocacy […]

Kick-Off Event for the SmartCARE Project

A Wind of Change in the EU's Pharmaceutical Landscape The challenge that the European Commission set itself up for in revising the EU’s Pharmaceutical Legislation (namely Directive 2001/83/EC1 and […]

Colores Finland Shares Effort to Support People Living with Lynch Syndrome

EuropaColon Poland Received "Swallow of Hope Award" Congratulations to our member organisation EuropaColon Poland Foundation for Patients, on receiving the “Swallow of Hope”, a national Polish awa […]

TOGAS: Towards Gastric Cancer Screening Implementation in the European Union

Liver Cancer Index – The Mapping Survey Is Available Online The survey was created to map the liver cancer treatment landscape across the EU and is now available online and disseminated among several relevant […]

Scientists Propose A Novel Approach For The Treatment Of Liver Cancer The Nature Cancer journal recently published promising results from cell and mouse studies by liver cancer specialists at the Massachusetts General […]

EuropaColon Slovenia Celebrates Its 15th Anniversary This March EuropaColon Slovenia rang in its 15th anniversary as a patient association! EC Slovenia was an original member of EuropaColon, the […]

Primary Findings From The GLOW Study Signals Positive Momentum In The Development Of Novel Therapeutic Options For Patients With HER2-Negative Locally Advanced Unresectable Or Metastatic Gastric & GEJ Cancers At the end of 2022, leaders of the Phase 3 clinical trial GLOW shared their positive primary findings. GLOW (NCT03653507) is a global, multicenter, […]

Trastuzumab Deruxtecan Meets Objective Response Rate Endpoint in Several Types of HER2-expressing Advanced Solid Tumours Positive topline results of the ongoing DESTINY-PanTumour02 Phase II trial (NCT04482309) showed that treatment with trastuzumab deruxtecan met the […]

The First International Management Guidelines for Early-Onset Colorectal Cancer This March, the Clinical Gastroenterology and Hepatology journal published the first management guidelines for Early-Onset Colorectal Cancer […]

FAPA On It's 30th Anniversary

Imfinzi & Imjudo Immunotherapy Drug Combinations Approved in the EU for the Treatment of Advanced Liver Cancer 

Zolbetuximab Plus Chemotherapy Extends Overall Survival for Patients with Advanced or Metastatic Gastric & Gastro-oesophageal Junction Adenocarcinoma The Annual American Society of Clinical Oncologists Gastrointestinal Cancers Symposium (ASCO GI) kicked off the year with lots of new data in the […]

<strong>First Immunotherapy Drug Durvalumab Plus Chemotherapy Approved in Europe for Advanced Biliary Cancer</strong> On 21 December the European Commission (EC) approved the use of durvalumab (Imfinzi ®) plus chemotherapy (gemcitabine plus cisplatin) as the first […]

<strong>Trastuzumab Deruxtecan Approved as Second-line Treatment in Europe For Patients With HER2-positive Advanced Gastric Cancer</strong> On December 19th the European Commission (EC) approved the use of trastuzumab deruxtecan (Enhertu ®) plus chemotherapy (gemcitabine plus cisplatin) […]